Potential TLR4-pathway inhibitors that have shown promise against early AD phenotypes include the omega-3-polyunsaturated fatty acid alpha-linolenic acid (Ali et al., 2020), geniposidic acid (Zhou et al., 2020), and Alpinia oxyphylla-Schisandra chinensis (Qi et al., 2019). Here, TLR4 is linked to Alzheimer disease.